Bronfman E.L. Rothschild L.P. increased its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 64.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,106 shares of the medical research company’s stock after acquiring an additional 1,215 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in Edwards Lifesciences were worth $350,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Victory Capital Management Inc. boosted its position in shares of Edwards Lifesciences by 4.6% during the 3rd quarter. Victory Capital Management Inc. now owns 557,773 shares of the medical research company’s stock valued at $60,969,000 after acquiring an additional 24,399 shares during the last quarter. Korea Investment CORP boosted its position in shares of Edwards Lifesciences by 144.5% during the 3rd quarter. Korea Investment CORP now owns 355,683 shares of the medical research company’s stock valued at $38,880,000 after acquiring an additional 210,200 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of Edwards Lifesciences by 53.3% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 11,991 shares of the medical research company’s stock valued at $1,418,000 after acquiring an additional 4,170 shares during the last quarter. Oakbrook Investments LLC lifted its position in Edwards Lifesciences by 25.7% in the third quarter. Oakbrook Investments LLC now owns 19,050 shares of the medical research company’s stock valued at $2,082,000 after buying an additional 3,900 shares during the last quarter. Finally, ING Groep NV lifted its position in Edwards Lifesciences by 41.2% in the third quarter. ING Groep NV now owns 22,905 shares of the medical research company’s stock valued at $2,504,000 after buying an additional 6,684 shares during the last quarter. 81.11% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Edwards Lifesciences Corp (EW) opened at $130.21 on Thursday. The stock has a market cap of $26,949.79, a PE ratio of 45.21, a PEG ratio of 1.88 and a beta of 0.63. Edwards Lifesciences Corp has a 1 year low of $89.20 and a 1 year high of $138.48. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.81.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The firm had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. During the same period in the prior year, the firm earned $0.75 earnings per share. The business’s quarterly revenue was up 15.7% compared to the same quarter last year. research analysts expect that Edwards Lifesciences Corp will post 4.49 EPS for the current fiscal year.

Edwards Lifesciences announced that its board has authorized a share buyback program on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.

In related news, VP Larry L. Wood sold 18,960 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $114.58, for a total transaction of $2,172,436.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $126.69, for a total transaction of $4,155,432.00. Following the sale, the chief executive officer now owns 74,131 shares in the company, valued at $9,391,656.39. The disclosure for this sale can be found here. Insiders have sold 205,530 shares of company stock worth $24,163,915 over the last 90 days. Insiders own 2.13% of the company’s stock.

EW has been the topic of a number of recent analyst reports. Cowen set a $135.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Sunday, December 10th. Evercore ISI initiated coverage on shares of Edwards Lifesciences in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $140.00 target price on the stock. Barclays raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $125.00 to $135.00 in a research report on Thursday, January 4th. Deutsche Bank decreased their target price on shares of Edwards Lifesciences from $122.00 to $115.00 and set a “hold” rating on the stock in a research report on Thursday, October 26th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $137.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, November 29th. Three research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Edwards Lifesciences has an average rating of “Buy” and an average target price of $141.15.

ILLEGAL ACTIVITY WARNING: “Bronfman E.L. Rothschild L.P. Purchases 1,215 Shares of Edwards Lifesciences Corp (EW)” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/02/15/bronfman-e-l-rothschild-l-p-purchases-1215-shares-of-edwards-lifesciences-corp-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.